Diagnostic utility of plasma metagenomic next-generation sequencing for bloodstream and localized infections in advanced HIV disease

Abstract Objectives To evaluate the diagnostic performance of plasma metagenomic next‑generation sequencing (mNGS) for suspected bloodstream infections (BSI) and localized infections in patients with advanced HIV disease. Methods We conducted a retrospective observational study of 110 patients with advanced HIV disease who underwent plasma mNGS. Plasma mNGS and conventional microbiological tests (CMTs) were performed concurrently. The diagnostic performance of plasma mNGS and CMTs was evaluated using a composite reference standard based on final clinical outcomes. In 26 patients with indeterminate plasma results, additional mNGS was performed on clinical specimens (BALF, CSF, pleural fluid, or tissue). Results Plasma mNGS detected clinically relevant pathogens in 81.8% (90/110) of patients. For BSI ( n = 69), sensitivity was 93.9% (95% CI: 84.9–98.3%) with 100% specificity (95% CI: 29.2–100% ); for localized infections ( n = 92), sensitivity was 85.9% (95% CI: 77.6–91.6%).with 100% sensitivity for talaromycosis and 96.2% for Pneumocystis jirovecii pneumonia. Of 263 microbial sequences detected, 124 (47.1%) were clinically relevant; 139 (52.9%)—almost exclusively viral (98.6%)—represented asymptomatic reactivation. All non‑viral sequences were clinically relevant. Co‑detection of multiple clinically relevant organisms occurred in 29 samples (32.2%). In 26 patients with specimen mNGS, concordance with final diagnosis was 96.2% (25/26). Plasma mNGS missed 17 confirmed infections, mostly involving compartmentalized sites (CNS, n = 5) or pathogens with complex cell walls ( n = 10). Conclusions Plasma mNGS demonstrated superior diagnostic performance over CMTs for detecting BSI and localized infections in advanced HIV disease, particularly for talaromycosis and Pneumocystis jirovecii pneumonia. Negative results do not exclude infection; clinical adjudication—particularly for viral detections—is essential. Specimen mNGS provides added value in compartmentalized infections.

Authors

Institutions

Publication Details

Journal
BMC Microbiology
Published
2026-09-12
DOI
https://doi.org/10.1186/s12866-026-05658-5
Primary Topic
Pneumocystis jirovecii pneumonia detection and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Diagnostic utility of plasma metagenomic next-generation sequencing for bloodstream and localized infections in advanced HIV disease

Bo He, Zhuyun Zhou, Yongfang Jiang, Man Chen et al.
BMC Microbiology
Pneumocystis jirovecii pneumonia detection and treatment
article

Diagnostic utility of plasma metagenomic next-generation sequencing for bloodstream and localized infections in advanced HIV disease

Bo He, Zhuyun Zhou, Yongfang Jiang, Man Chen, Hua-Ying Zhou, Yan He
article en

Abstract

Abstract Objectives To evaluate the diagnostic performance of plasma metagenomic next‑generation sequencing (mNGS) for suspected bloodstream infections (BSI) and localized infections in patients with advanced HIV disease. Methods We conducted a retrospective observational study of 110 patients with advanced HIV disease who underwent plasma mNGS. Plasma mNGS and conventional microbiological tests (CMTs) were performed concurrently. The diagnostic performance of plasma mNGS and CMTs was evaluated using a composite reference standard based on final clinical outcomes. In 26 patients with indeterminate plasma results, additional mNGS was performed on clinical specimens (BALF, CSF, pleural fluid, or tissue). Results Plasma mNGS detected clinically relevant pathogens in 81.8% (90/110) of patients. For BSI ( n = 69), sensitivity was 93.9% (95% CI: 84.9–98.3%) with 100% specificity (95% CI: 29.2–100% ); for localized infections ( n = 92), sensitivity was 85.9% (95% CI: 77.6–91.6%).with 100% sensitivity for talaromycosis and 96.2% for Pneumocystis jirovecii pneumonia. Of 263 microbial sequences detected, 124 (47.1%) were clinically relevant; 139 (52.9%)—almost exclusively viral (98.6%)—represented asymptomatic reactivation. All non‑viral sequences were clinically relevant. Co‑detection of multiple clinically relevant organisms occurred in 29 samples (32.2%). In 26 patients with specimen mNGS, concordance with final diagnosis was 96.2% (25/26). Plasma mNGS missed 17 confirmed infections, mostly involving compartmentalized sites (CNS, n = 5) or pathogens with complex cell walls ( n = 10). Conclusions Plasma mNGS demonstrated superior diagnostic performance over CMTs for detecting BSI and localized infections in advanced HIV disease, particularly for talaromycosis and Pneumocystis jirovecii pneumonia. Negative results do not exclude infection; clinical adjudication—particularly for viral detections—is essential. Specimen mNGS provides added value in compartmentalized infections.

BMC Microbiology
Central South University (CN), Changsha Medical University (CN), Second Xiangya Hospital of Central South University (CN)
Good health and well-being
Openalex Percentile: Top 10%
Pneumocystis jirovecii pneumonia detection and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.